India-based Lupin Manufacturing Solutions (LMS) has formed a partnership with PolyPeptide Group to expand the global supply chain for peptide-based active pharmaceutical ingredients (APIs).
Peptides are short chains of amino acids, typically comprising between two and 49 units, making them smaller than proteins, which usually contain 50 or more amino acids.
Under the long-term agreement, the two companies will collaborate to broaden sourcing options for peptide APIs.
They will also align procurement and supply planning processes.
Lupin Manufacturing Solutions CEO Abdelaziz Toumi said: “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production.”
The alliance is designed to improve supply chain resilience as global demand for peptide APIs increases, including demand linked to metabolic disease treatments.
It also aims to maintain consistent quality, reliability and global service delivery across markets, the press statement added.
The agreement is expected to strengthen LMS’s position as a contract development and manufacturing organisation (CDMO) supplying peptide materials for innovator and generic customers.
PolyPeptide chief commercial officer Stéphane Varray added: “Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including preparations for large-scale metabolics. When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”
Lupin Manufacturing Solutions is a wholly owned subsidiary of Lupin Limited.
It operates as an API manufacturer and global CDMO, offering standalone and integrated services.
The group’s capabilities span drug substances, complex chemistry, drug products and advanced modalities, including antibody-drug conjugates and peptides.
PolyPeptide Group, founded in 1952, is a specialised CDMO focused on peptide- and oligonucleotide-based APIs.
The group operates six GMP-certified manufacturing sites across Europe, the US and India.
In another development related to amino acids earlier this month, Croda International, a UK-based producer of high-performance ingredients, entered into a supply alliance with Germany-based Amino.
The partnership is aimed at expanding global access to high-purity, pharmaceutical-grade amino acids used in drug formulation and biomanufacturing, Croda noted.
